The landscape of pricing is changing rapidly. List prices and External Reference Pricing (ERP) are going to fade away. Value Based Pricing (VBP) and Negotiation are becoming they key driver. Multiple indications are asking for differential pricing.
pharmaLevers has a long history of managed entry schemes: pay for performance, capitation, money back guarantee, cost-sharing, pay-backs and others with BioTech products in oncology.
pharmaLevers is helping clients in the following way:
- develop a sustainable Pricing Strategy including Multi-Indication Pricing & Indication specific pricing
- create Managed Entry Schemes including Pay-for-Performance and Coverage with Evidence Development
- get Payers and Decision Makers on board
- design and create a simpler processes